168.1500 0.11 (0.07%)
NSE Apr 02, 2026 15:31 PM
Volume: 550.7K
 

Karvy
Karvy Initiates coverage of Marksans with a Buy rating: We expect its softgel capabilities to improve its presence in USA. Clear of the debt overhang on the company financials and propelled by the subsidiaries return to growth, the company is expected to move into the next phase of growth and sustain its higher return ratios.
Number of FII/FPI investors decreased from 146 to 137 in Dec 2025 qtr
More from Marksans Pharma Ltd.
Recommended